Nothing Special   »   [go: up one dir, main page]

SG11202000230VA - Carboxamides as modulators of sodium channels - Google Patents

Carboxamides as modulators of sodium channels

Info

Publication number
SG11202000230VA
SG11202000230VA SG11202000230VA SG11202000230VA SG11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA SG 11202000230V A SG11202000230V A SG 11202000230VA
Authority
SG
Singapore
Prior art keywords
carboxamides
modulators
sodium channels
channels
sodium
Prior art date
Application number
SG11202000230VA
Inventor
Nadia Ahmad
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Asgian
Joanne Camp
Lev Tyler Fanning
Ruah Sara Hadida
Dennis Hurley
Yvonne Schmidt
David Shaw
Urvi Patel
Stephen Thomson
Lidio Marx Carvalho Meireles
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG11202000230VA publication Critical patent/SG11202000230VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
SG11202000230VA 2017-07-11 2018-07-11 Carboxamides as modulators of sodium channels SG11202000230VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531313P 2017-07-11 2017-07-11
US201762608283P 2017-12-20 2017-12-20
PCT/US2018/041649 WO2019014352A1 (en) 2017-07-11 2018-07-11 Carboxamides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
SG11202000230VA true SG11202000230VA (en) 2020-02-27

Family

ID=63036498

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000230VA SG11202000230VA (en) 2017-07-11 2018-07-11 Carboxamides as modulators of sodium channels

Country Status (23)

Country Link
US (3) US10647661B2 (en)
EP (1) EP3651752A1 (en)
JP (1) JP7277431B2 (en)
KR (1) KR20200026987A (en)
CN (1) CN111065383A (en)
AU (1) AU2018300150A1 (en)
BR (1) BR112020000553A2 (en)
CA (1) CA3069720A1 (en)
CL (1) CL2020000075A1 (en)
CO (1) CO2020000145A2 (en)
CR (1) CR20200064A (en)
DO (1) DOP2020000004A (en)
EC (1) ECSP20003147A (en)
IL (1) IL271948A (en)
JO (1) JOP20200001A1 (en)
MA (1) MA49566A (en)
PE (1) PE20201164A1 (en)
PH (1) PH12020500066A1 (en)
SG (1) SG11202000230VA (en)
TN (1) TN2020000001A1 (en)
TW (1) TW201920081A (en)
UY (1) UY37806A (en)
WO (1) WO2019014352A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033370T2 (en) 2013-01-31 2017-11-28 Vertex Pharma Pyridone amides as modulators of sodium channels
US11203571B2 (en) 2013-07-19 2021-12-21 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
AU2014362255B2 (en) 2013-12-13 2019-08-29 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
MA49137A (en) 2017-05-16 2021-04-21 Vertex Pharma DEUTERATED PYRIDONE AMIDES AND THEIR PREDICTIONS USED AS SODIUM CHANNEL MODULATORS
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
AU2019218387A1 (en) 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain
HUE061046T2 (en) 2018-02-15 2023-05-28 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
KR20210019119A (en) 2018-07-09 2021-02-19 리버 인스티튜트, 아이엔씨 Pyridazine (PYRIDAZINE) compounds to inhibit Nav1.8
AU2019301628B2 (en) * 2018-07-09 2024-10-31 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
BR112021008524A8 (en) * 2018-11-02 2023-02-07 Merck Sharp & Dohme 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV 1.8 INHIBITORS
US20220110923A1 (en) * 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020151728A1 (en) * 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 2-oxo-1,2-dihydropyridin derivative, preparation method therefor and medical uses thereof
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
TW202120517A (en) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 Process of making cftr modulators
JP2022544383A (en) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Crystal forms of CFTR modulators
TW202115038A (en) * 2019-08-19 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 Benzamide fused aromatic ring derivatives, preparation process and medical use thereof
MX2022003032A (en) * 2019-09-12 2022-07-12 Shanghai Jemincare Pharmaceuticals Co Ltd Pyridine oxynitride, preparation method therefor and use thereof.
CN110950797A (en) * 2019-12-06 2020-04-03 丽水绿氟科技有限公司 Preparation method of 2-trifluoromethyl-3-fluoro-4-picolinic acid and derivatives thereof
PE20230300A1 (en) 2019-12-06 2023-02-13 Vertex Pharma SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
CN110937994B (en) * 2019-12-10 2022-04-22 浙江大洋生物科技集团股份有限公司 Method for synthesizing 2, 4-dichloro-6-fluorobenzoyl chloride by two-step chlorination process
CN114437062B (en) * 2020-04-30 2024-05-17 成都海博为药业有限公司 Compound capable of being used as sodium channel regulator and application thereof
BR112022022595A2 (en) 2020-05-06 2022-12-20 Bayer Ag PYRIDINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS
EP4149929A1 (en) 2020-05-12 2023-03-22 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds
BR112022025805A2 (en) 2020-06-17 2023-01-10 Merck Sharp & Dohme Llc COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREAT OR PREVENT A DISORDER, CONDITION OR DISEASE
CN113880771B (en) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 Selective Na v Crystalline forms of inhibitors and methods of making the same
CN111920796A (en) * 2020-08-28 2020-11-13 南京医科大学 Application of compound in preparation of medicine for treating epilepsy
CN111808019B (en) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 Fused ring compound and application thereof
CN114031518B (en) * 2020-12-08 2023-08-18 成都海博为药业有限公司 Benzylamine or benzyl alcohol derivative and application thereof
CA3211594A1 (en) 2021-03-11 2022-09-15 Yong Zhang Crystal form of pyridine nitrogen oxide compound and use thereof
IL307338A (en) 2021-04-05 2023-11-01 Bristol Myers Squibb Co Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
TWI827037B (en) 2021-05-07 2023-12-21 美商默沙東有限責任公司 Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN117794919A (en) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N- (hydroxyalkyl (hetero) aryl) tetrahydrofurancarboxamide analogues as sodium channel modulators
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
JP2024520649A (en) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド Solid dosage forms and administration regimens comprising (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
CN117794921A (en) * 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 Methods for synthesizing substituted sodium tetrahydrofurane channel modulators
KR20240031300A (en) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 N-(Hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide as a sodium channel modulator
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
CN117794918A (en) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 Substituted tetrahydrofuran analogues as sodium channel modulators
AR126670A1 (en) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS
AR126669A1 (en) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A N-ACYLYDRAZONIC COMPOUNDS INHIBITORS OF Nav 1.7 AND/OR Nav 1.8, THEIR OBTAINING PROCESSES, COMPOSITIONS, USES, TREATMENT METHODS OF THESE AND KITS
CN116462662A (en) 2022-01-18 2023-07-21 成都康弘药业集团股份有限公司 Aromatic ring Nav1.8 inhibitor and application thereof
CN116891432A (en) * 2022-04-02 2023-10-17 武汉人福创新药物研发中心有限公司 Nav1.8 inhibitors and uses thereof
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202408501A (en) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
CN116947713A (en) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 Ring-merging compound and application thereof
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023246867A1 (en) * 2022-06-22 2023-12-28 武汉人福创新药物研发中心有限公司 Nav1.8 inhibitor
WO2024041613A1 (en) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 Heterocyclic compound, method for preparing same, and pharmaceutical use thereof
WO2024046253A1 (en) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 Sodium channel regulator and use thereof
WO2024046409A1 (en) * 2022-08-31 2024-03-07 江苏恒瑞医药股份有限公司 Heterocyclic compound, preparation method therefor, and pharmaceutical use thereof
WO2024054622A2 (en) * 2022-09-09 2024-03-14 Latigo Biotherapeutics, Inc. Sodium channel blocking compounds, derivatives thereof, and methods of their use
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2024146632A1 (en) * 2023-01-06 2024-07-11 西藏海思科制药有限公司 Tetrahydrothiophene derivative and use thereof in medicine
WO2024153856A1 (en) * 2023-01-18 2024-07-25 Orion Corporation Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide
WO2024217344A1 (en) * 2023-04-19 2024-10-24 中国科学院上海药物研究所 Nav1.8 inhibitors, preparation method therefor and use thereof

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1025305A (en) 1910-07-29 1912-05-07 Andrew Rasmussen Feeding means for power hacksaw-machines.
US1008714A (en) 1910-12-27 1911-11-14 Henry M Hammer Delinting-machine.
US2511231A (en) 1949-03-26 1950-06-13 Eastman Kodak Co 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography
US2688617A (en) 1951-07-17 1954-09-07 American Cyanamid Co Sulfonated dihalogeno diaminostilbenes
US2657134A (en) 1951-12-05 1953-10-27 Eastman Kodak Co Photographic emulsion with colored couplers containing isophthalic ester groups
BE516025A (en) 1951-12-05
US2725292A (en) 1952-05-15 1955-11-29 Eastman Kodak Co Colored couplers containing solubilizing groups
US2710802A (en) 1953-03-16 1955-06-14 Eastman Kodak Co Dialkyl-5-(oxanilamido) isophthalate couplers for color photography
US2710803A (en) 1953-03-26 1955-06-14 Eastman Kodak Co Color couplers containing hydroxyalkyl groups
BE528163A (en) 1953-04-17
BE531589A (en) 1953-09-02
US4218765A (en) 1974-10-03 1980-08-19 Standard Oil Company (Indiana) Two-dimensional frequency domain filtering
DE2623228C3 (en) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-acyl-substituted benzamides, processes for their preparation and pharmaceuticals containing such benzamides
US4639273A (en) 1983-05-06 1987-01-27 Morton Thiokol, Inc. Asphalt-adhesion improving additives prepared by formaldehyde condensation with polyamines
JPS63182182A (en) 1987-01-23 1988-07-27 Fuji Photo Film Co Ltd Thermal recording material
FR2628864B1 (en) 1988-03-21 1990-06-15 France Etat METHOD FOR SEGMENTATION OF A FIELD OF SPEED VECTORS, IN PARTICULAR OF SPEEDS FOR MOVING POINTS OF AN IMAGE IN A SEQUENCE OF IMAGES
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
JP2766323B2 (en) 1989-07-19 1998-06-18 株式会社東芝 Display adjustment device
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
DE4019307A1 (en) 1990-06-16 1991-12-19 Bayer Ag 2-METHOXIMINOCARBONIC ACID ESTER
US5449691A (en) 1991-12-31 1995-09-12 Sterling Winthrop Inc. 3,4-disubstituted anilines-immunomodulating agents
US5258407A (en) 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
FR2687932A1 (en) 1992-02-27 1993-09-03 Oreal OIL-IN-WATER DISPERSION CAPABLE OF FORMING COMPOSITE FILMS.
JPH05313169A (en) 1992-05-08 1993-11-26 Fuji Photo Film Co Ltd Liquid crystal oriented film
HUT63941A (en) 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
GB9408185D0 (en) 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
KR100287579B1 (en) 1994-05-31 2001-05-02 야스이 쇼사꾸 Naphthalene derivative
US5536718A (en) 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AR002459A1 (en) 1995-01-17 1998-03-25 American Cyanamid Co TRASCINIC BENZACEPINE VASOPRESIN ANTAGONISTS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, A METHOD FOR TREATING DISEASES AND A PROCEDURE FOR THEIR PREPARATION.
US5532235A (en) 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19523640A1 (en) 1995-06-29 1997-01-02 Bayer Ag Substituted carbonylaminophenyluracile
DE19621522A1 (en) 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh New N-acylsulfonamides, new mixtures of herbicides and antidots and their use
JP3731963B2 (en) 1997-01-14 2006-01-05 株式会社シマノ Fishing rod plug
JPH10213820A (en) 1997-01-31 1998-08-11 Canon Inc Liquid crystal element and liquid crystal device
CA2285424A1 (en) 1997-04-22 1998-10-29 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
WO1999047529A1 (en) 1998-03-18 1999-09-23 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
JP2002512997A (en) 1998-04-29 2002-05-08 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitor of IMPDH enzyme
JP2002179651A (en) 1998-06-19 2002-06-26 Wakamoto Pharmaceut Co Ltd Benzanilide derivative and medicine composition
NZ510098A (en) 1998-10-22 2003-09-26 Neurosearch As Substituted phenyl derivatives, pharmaceuticals thereof and their use as blockers of the chloride channel
CN1183113C (en) 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 Tri-aryl acid derivatives as PPAR receptor ligands
WO2001007028A2 (en) 1999-07-23 2001-02-01 Allergan Sales, Inc. The use of retinoid receptor antagonists in the treatment of prostate carcinoma
BR0014076A (en) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamides and related factor xa inhibitors
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20020065303A1 (en) 2000-02-01 2002-05-30 Bing-Yan Zhu Bivalent phenylene inhibitors of factor Xa
DK1259485T3 (en) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamides and related inhibitors of factor Xa
CA2402315A1 (en) 2000-03-09 2001-09-13 Michael Jaye Therapeutic uses of ppar mediators
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
DE10033337A1 (en) 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarboxamides, their preparation and their use as medicaments
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US20040058903A1 (en) 2000-10-05 2004-03-25 Hisashi Takasugi Benzamide compounds as apo b secretion inhibitors
WO2002034711A1 (en) 2000-10-20 2002-05-02 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
JP2004514669A (en) 2000-11-07 2004-05-20 ブリストル−マイヤーズ スクイブ カンパニー Acid derivatives useful as serine protease inhibitors
CA2425892A1 (en) 2000-11-28 2003-04-11 Hiroyuki Koshio 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivative or salt thereof
KR20040015036A (en) 2000-12-06 2004-02-18 아벤티스 파마 도이칠란트 게엠베하 Guanidine and amidine derivatives as factor Xa inhibitors
CN1289072C (en) 2000-12-22 2006-12-13 石原产业株式会社 Aniline derivatives or salts thereof and cytokine prodn inhibitors contg. same
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002054077A2 (en) 2000-12-29 2002-07-11 7Tm Pharma A/S Validating biological molecules as drug targets by metal-ion chelates in animal test models
IL156994A0 (en) 2001-03-05 2004-02-08 Du Pont Heterocyclic diamide invertebrate pest control agent
EP1383731B1 (en) 2001-04-06 2009-08-05 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
JP2004532856A (en) 2001-04-30 2004-10-28 藤沢薬品工業株式会社 Biarylcarboxamide compounds as apolipoprotein B inhibitors
WO2002098839A1 (en) 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
US20030236198A1 (en) 2001-06-13 2003-12-25 Genesoft, Inc. Antipathogenic benzamide compounds
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
DE10132686A1 (en) 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarboxamides, their preparation and their use as medicines
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003013516A1 (en) 2001-08-10 2003-02-20 Adipogenix, Inc. Fat accumulation-modulating compounds
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
WO2003057205A2 (en) 2002-01-10 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
JP2005516037A (en) 2002-01-22 2005-06-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Diamide Invertebrate Pest Control Agent
MXPA04002602A (en) 2002-02-28 2004-08-11 Japan Tobacco Inc Ester compound and medicinal use thereof.
EP1485079B1 (en) 2002-03-11 2014-04-02 Janssen R&D Ireland Small molecule entry inhibitors
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
JP2003342175A (en) 2002-05-24 2003-12-03 Yamanouchi Pharmaceut Co Ltd Therapeutic agent for meniere disease comprising new benzazepine derivative or its salt as active ingredient
JP2004043456A (en) 2002-05-24 2004-02-12 Yamanouchi Pharmaceut Co Ltd Medicine containing benzazepine derivative or its salt as active component
WO2004000820A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
EP1546089A2 (en) 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
JP2004175739A (en) 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd Medicinal composition
KR101057747B1 (en) 2002-12-12 2011-08-19 시바 홀딩 인코포레이티드 Amino Substituted Hydroxyphenyl Benzophenone Derivatives
AU2003286311A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
SG2012000667A (en) 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP2004315395A (en) 2003-04-14 2004-11-11 Yamanouchi Pharmaceut Co Ltd New benzoic acid derivative or its salt
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
CA2538820A1 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd Novel antifungal agent comprising heterocyclic compound
WO2005040135A1 (en) 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. Antistress drug and medical use thereof
NZ548793A (en) 2004-01-28 2009-12-24 Mitsui Chemicals Inc Amide derivatives, process for preparation thereof and use thereof as insecticide
DE102004009238A1 (en) 2004-02-26 2005-09-08 Merck Patent Gmbh New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
US7649004B2 (en) 2004-07-23 2010-01-19 Pfizer, Inc. Pyridine derivatives
DE102004050196A1 (en) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituted 2-pyridone derivatives, process for their preparation and their use as medicaments
US20080125432A1 (en) 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
WO2006068199A1 (en) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. Metabolically stable 3-oxy-1,2,4-triazole derivatives
BRPI0611596A2 (en) 2005-06-21 2010-09-21 Mitsui Chemicals Inc amine and insecticide derivative containing the same
US7750004B2 (en) 2005-07-07 2010-07-06 Abbott Laboratories Apoptosis promoters
JP4580836B2 (en) 2005-07-25 2010-11-17 三井化学アグロ株式会社 Insecticidal composition
US20080249137A1 (en) 2005-09-07 2008-10-09 Jack Lin PPAR active compounds
EP1942732A2 (en) 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007052843A1 (en) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
EP1966184B1 (en) 2005-12-20 2010-08-25 NeuroSearch A/S Pyridinyl-quinazoline derivatives and their medical use
UY30117A1 (en) 2006-01-31 2007-06-29 Tanabe Seiyaku Co AMIS TRISUSTITUDED COMPOUND
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
MX2008013194A (en) 2006-04-11 2008-12-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated sodium channels.
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
US20090325956A1 (en) 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
JP2008106017A (en) 2006-10-27 2008-05-08 Tokyo Univ Of Science Compound having selective oatp-inhibiting property, and selective oatp-inhibiting agent containing the compound
EP2101760B1 (en) 2006-12-08 2013-02-27 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP4325681B2 (en) 2007-02-13 2009-09-02 ソニー株式会社 Solid-state imaging device, imaging device
CN101622231B (en) 2007-02-28 2013-12-04 艾德维纳斯医疗私人有限公司 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
MX2009011816A (en) 2007-05-03 2009-11-19 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators.
WO2008140810A1 (en) 2007-05-11 2008-11-20 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
EP2173721B1 (en) 2007-06-26 2011-12-28 Sanofi A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
JP5473921B2 (en) 2007-10-10 2014-04-16 ビーエーエスエフ ソシエタス・ヨーロピア Sulfonium salt initiator
KR101571912B1 (en) 2007-10-10 2015-11-25 바스프 에스이 Sulphonium salt initiators
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
NZ584519A (en) 2007-10-11 2012-07-27 Vertex Pharma Aryl amides useful as inhibitors of voltage-gated sodium channels
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
JP2009108152A (en) 2007-10-29 2009-05-21 Sumitomo Chemical Co Ltd Polymerizable compound and optical film
WO2009070533A1 (en) 2007-11-29 2009-06-04 Complegen, Inc. Methods of inhibiting steroyl coa desaturase
JP2009149754A (en) 2007-12-20 2009-07-09 Sumitomo Chemical Co Ltd Polymerizable compound and optical film produced by polymerizing the polymerizable compound
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2009209090A (en) 2008-03-04 2009-09-17 Mitsui Chemicals Inc Insecticide, compound contained in the insecticide, and method of using the compound
US20100009970A1 (en) 2008-03-19 2010-01-14 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
JP5219583B2 (en) 2008-03-31 2013-06-26 住友化学株式会社 Composition, optical film and method for producing the same, optical member and display device
JP2010001284A (en) 2008-05-20 2010-01-07 Sumitomo Chemical Co Ltd Compound and optical film
HUE060249T2 (en) 2008-06-16 2023-02-28 Univ Tennessee Res Found Compounds for treatment of cancer
MX2011002060A (en) 2008-08-25 2011-04-05 Irm Llc Hedgehog pathway modulators.
JP5443720B2 (en) 2008-09-05 2014-03-19 住友化学株式会社 Composition, optical film and method for producing the same, optical member, and display device
JP2010066630A (en) 2008-09-12 2010-03-25 Sumitomo Chemical Co Ltd Method for manufacturing optical film, and optical film
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
PL2340021T3 (en) 2008-09-18 2013-04-30 Hoffmann La Roche Substituted pyrrolidine-2-carboxamides
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5649779B2 (en) 2008-11-28 2015-01-07 住友化学株式会社 Liquid crystalline composition and optical film
KR101663336B1 (en) 2008-12-26 2016-10-06 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Novel bicyclic heterocyclic compound
TWI482769B (en) 2009-03-16 2015-05-01 Sumitomo Chemical Co Compound, optical film and method for making an optical film
JP5899607B2 (en) 2009-03-16 2016-04-06 住友化学株式会社 Compound, optical film and method for producing optical film
UA105527C2 (en) 2009-05-18 2014-05-26 Оріон Корпорейшн Matriptase inhibitor compound for the treatment of cancer
EP2253617A1 (en) 2009-05-20 2010-11-24 Bayer CropScience AG Halogenated compounds as pesticides
WO2010138901A1 (en) 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
JP2011006360A (en) 2009-06-26 2011-01-13 Sumitomo Chemical Co Ltd Compound, optical film and method for producing optical film
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
KR101256018B1 (en) 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011032169A2 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US8420647B2 (en) 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
JP5375644B2 (en) 2010-02-10 2013-12-25 住友化学株式会社 Composition and optical film
CN102883607B (en) 2010-03-01 2015-07-22 Gtx公司 Compounds for treatment of cancer
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2812526A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2616453A4 (en) 2010-08-24 2014-07-02 Univ Brigham Young Antimetastatic compounds
WO2012026931A1 (en) 2010-08-25 2012-03-01 Synta Pharmaceuticals Corp. Method of synthesizing substituted 2-alkyl phenols
EP2651404B1 (en) 2010-12-14 2015-10-14 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
TW201604196A (en) 2011-02-02 2016-02-01 維泰克斯製藥公司 Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
MX2013009393A (en) 2011-02-18 2013-08-29 Vertex Pharma Chroman - spirocyclic piperidine amides as modulators of ion channels.
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd Benzimidazole inhibitors of the sodium channel
WO2012125613A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
US20140113934A1 (en) 2011-06-20 2014-04-24 E I Du Pont De Nemours And Company Heterocyclic compounds for treating helminth infections
CA2839451A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
DK2573073T3 (en) 2011-09-26 2015-01-19 Sanofi Sa Pyrazolquinolinonderivater, their preparation and therapeutic use thereof
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (en) 2011-09-26 2017-03-01 赛诺菲 Pyrazolo (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide, its preparation method and its therapeutic use
US9079878B2 (en) 2011-10-26 2015-07-14 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
WO2013086229A1 (en) 2011-12-07 2013-06-13 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
EP2606726A1 (en) 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
JP2015503519A (en) 2011-12-23 2015-02-02 ノバルティス アーゲー Compound for inhibiting interaction between BCL2 and binding partner
AU2013209958B2 (en) 2012-01-16 2017-09-07 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
ES2548228T3 (en) 2012-02-03 2015-10-15 Pfizer Inc Benzimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
US8481479B1 (en) 2012-03-07 2013-07-09 Shaker A. Mousa Formulations of factor VIIa inhibitors and utility
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
WO2014041125A1 (en) 2012-09-13 2014-03-20 Baden-Württemberg Stiftung Gmbh Specific inhibitors of protein p21 as therapeutic agents
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
WO2014055644A2 (en) 2012-10-02 2014-04-10 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201505952WA (en) 2013-01-31 2015-08-28 Vertex Pharma Quinoline and quinazoline amides as modulators of sodium channels
CN104968647B (en) 2013-01-31 2018-01-26 沃泰克斯药物股份有限公司 Acid amides as sodium channel modulators
HUE033370T2 (en) 2013-01-31 2017-11-28 Vertex Pharma Pyridone amides as modulators of sodium channels
CN103961348B (en) 2013-02-05 2016-08-17 上海交通大学医学院 SENP1 micromolecular inhibitor and application thereof
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
JP5902641B2 (en) 2013-03-27 2016-04-13 富士フイルム株式会社 Optical interference pigment and method for producing the same
JP2014232188A (en) 2013-05-29 2014-12-11 コニカミノルタ株式会社 Cellulose acylate film, circularly polarizing plate and image display device
JP6387960B2 (en) 2013-05-31 2018-09-12 コニカミノルタ株式会社 Resin composition, optical member, optical film, polarizing plate, circularly polarizing plate, and image display device
WO2015030898A2 (en) 2013-06-07 2015-03-05 The Regents Of The University Of California Micromechanical resonant switches and charge pumps
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20160145304A1 (en) 2013-07-12 2016-05-26 Helmholtz-Zentrum für Infektionsforschung GmbH Cystobactamides
US11203571B2 (en) 2013-07-19 2021-12-21 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
CN105611924A (en) 2013-07-25 2016-05-25 泰莱托恩基金会 Inhibitors of FAPP2 and uses thereof
WO2015014900A1 (en) 2013-07-31 2015-02-05 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
KR101628288B1 (en) 2013-09-30 2016-06-08 주식회사 엘지화학 Composition for manufacturing optical elements with negative optical dispersion and optically anisotropic body manufactured therefrom
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
AU2014362255B2 (en) 2013-12-13 2019-08-29 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9204150B2 (en) 2014-02-26 2015-12-01 Intel Corporation Techniques for evaluating compressed motion video quality
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2016022626A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP2997966A1 (en) 2014-09-16 2016-03-23 Sanofi Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders
CN106317027A (en) 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 Heteroaryl amide derivative and use thereof as TGR5 agonist
EP3350181B1 (en) 2015-09-02 2023-11-01 The Regents of The University of California Her3 ligands and uses thereof
US11413278B2 (en) 2015-10-08 2022-08-16 The Regents Of The University Of California Compounds and methods for promoting stress resistance
US20180305334A1 (en) 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
US10781218B2 (en) 2016-03-16 2020-09-22 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
AU2017336523B2 (en) 2016-09-28 2022-07-21 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
KR102458810B1 (en) 2016-09-28 2022-10-26 메르크 파텐트 게엠베하 Polymerizable liquid crystal material and polymerized liquid crystal film
WO2018161033A1 (en) 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
BR112019021899A2 (en) 2017-04-20 2020-08-18 The Regents Of The University Of California k-ras modulators
WO2018202681A1 (en) 2017-05-04 2018-11-08 Bayer Cropscience Aktiengesellschaft Use of disubstituted benzenes to control insecticide-resistant pests
JP2019015998A (en) 2017-07-03 2019-01-31 東芝テック株式会社 Information processing system and program
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc Methods of treating epilepsy and kcnti related conditions
CN111163766A (en) 2017-08-17 2020-05-15 医肯纳肿瘤学公司 AHR inhibitors and uses thereof
AU2019213694B2 (en) 2018-01-30 2023-04-06 Pi Industries Ltd. Novel anthranilamides, their use as insecticide and processes for preparing the same.
AU2019218387A1 (en) 2018-02-12 2020-08-27 Vertex Pharmaceuticals Incorporated A method of treating pain
CN112041413A (en) 2018-04-27 2020-12-04 默克专利股份有限公司 Polymerizable liquid crystal material and polymerized liquid crystal film
CN112041414B (en) 2018-04-27 2024-07-19 默克专利股份有限公司 Polymerizable liquid crystal material and polymerized liquid crystal film
WO2019241787A1 (en) 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
EP3847159A2 (en) 2018-09-04 2021-07-14 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use
WO2020081572A1 (en) 2018-10-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof
WO2020123675A1 (en) 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
CA3124970A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
US20230062053A1 (en) 2019-01-10 2023-03-02 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
CN113302262A (en) 2019-01-22 2021-08-24 默克专利股份有限公司 Method for preparing liquid crystal polymer film
AU2019427489A1 (en) 2019-01-28 2021-07-22 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
MX2021011209A (en) 2019-03-15 2022-01-19 Massachusetts Gen Hospital Novel small molecule inhibitors of tead transcription factors.
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
KR20220019234A (en) 2019-04-30 2022-02-16 메르크 파텐트 게엠베하 reactive mesogen
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof

Also Published As

Publication number Publication date
IL271948A (en) 2020-02-27
US11603351B2 (en) 2023-03-14
JP2020526561A (en) 2020-08-31
CN111065383A (en) 2020-04-24
US20230286907A1 (en) 2023-09-14
KR20200026987A (en) 2020-03-11
ECSP20003147A (en) 2020-02-28
US10647661B2 (en) 2020-05-12
US20190016671A1 (en) 2019-01-17
DOP2020000004A (en) 2020-07-15
CL2020000075A1 (en) 2020-07-31
CA3069720A1 (en) 2019-01-17
UY37806A (en) 2020-01-31
US20210094906A1 (en) 2021-04-01
CR20200064A (en) 2020-08-03
TN2020000001A1 (en) 2021-10-04
MA49566A (en) 2020-05-20
TW201920081A (en) 2019-06-01
BR112020000553A2 (en) 2020-07-21
JOP20200001A1 (en) 2022-10-30
JP7277431B2 (en) 2023-05-19
AU2018300150A1 (en) 2020-01-30
EP3651752A1 (en) 2020-05-20
WO2019014352A1 (en) 2019-01-17
CO2020000145A2 (en) 2020-01-17
PE20201164A1 (en) 2020-10-28
PH12020500066A1 (en) 2020-09-28

Similar Documents

Publication Publication Date Title
IL271948A (en) Carboxamides as modulators of sodium channels
IL283582A (en) Modulators of ror-gamma
HK1256599A1 (en) Modulators of ror-gamma
HK1255699A1 (en) Modulators of kras expression
HK1217692A1 (en) Amides as modulators of sodium channels
HK1223604A1 (en) Sulfonamides as modulators of sodium channels
GB201609764D0 (en) 3D printing of gel networks
IL259762B (en) Modulators of complement activity
HK1246672A1 (en) Modulators of complement activity
IL281492A (en) Modulators of pnpla3 expression
IL283967A (en) Modulators of hsd17b13 expression
IL304618A (en) Modulators of pcsk9 expression
EP3364974A4 (en) Modulators of telomere disease
PT3334734T (en) Form c of avibactam sodium